Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2007

Boston Scientific and Angiotech Win Dutch Patent Infringement Case Against Conor

  • Boston Scientific and Angiotech Pharmaceuticals won a patent infringement case against Conor Medsystems in The Netherlands. The District Court in The Hague ruled that Conor's CoStar™ paclitaxel stent infringed a key claim of the Dutch version of Angiotech's European paclitaxel stent patent and upheld the validity of that claim.

    The Court thus prohibited Conor from selling the infringing CoStar paclitaxel stent in The Netherlands. The Court also ordered Conor to pay damages and/or surrender profits resulting from the infringement.

    On Tuesday, January 16, a U.K. court denied Angiotech’s appeal of a ruling that invalidated in Britain one of several patents related to its paclitaxel-eluting stents. The patent, which is part of a worldwide patent portfolio exclusively licensed to Boston Scientific, is still valid and enforceable in all designated European jurisdictions except the U.K.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »